Cargando…

Hypoxia in Diabetic Kidneys

Diabetic nephropathy (DN) is now a leading cause of end-stage renal disease. In addition, DN accounts for the increased mortality in type 1 and type 2 diabetes, and then patients without DN achieve long-term survival compatible with general population. Hypoxia represents an early event in the develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takiyama, Yumi, Haneda, Masakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094876/ https://www.ncbi.nlm.nih.gov/pubmed/25054148 http://dx.doi.org/10.1155/2014/837421

Ejemplares similares

Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice
por: Atageldiyeva, Kuralay, et al.
Publicado: (2016)

Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells
por: Watanabe, Jun, et al.
Publicado: (2016)

Therapeutic management of diabetic kidney disease
por: Koya, Daisuke, et al.
Publicado: (2011)

Tubular Injury in a Rat Model of Type 2 Diabetes Is Prevented by Metformin: A Possible Role of HIF-1α Expression and Oxygen Metabolism
por: Takiyama, Yumi, et al.
Publicado: (2011)

Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy
por: Bessho, Ryoichi, et al.
Publicado: (2019)

Alternative form of glucose‐dependent insulinotropic polypepide and its physiology
por: Fujita, Yukihiro, et al.
Publicado: (2016)

Increment of plasma glucose by exogenous glucagon is associated with present and future renal function in type 2 diabetes:a retrospective study from glucagon stimulation test
por: Takeda, Yasutaka, et al.
Publicado: (2019)

Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects
por: Yanagimachi, Tsuyoshi, et al.
Publicado: (2016)

High glucose induces platelet‐derived growth factor‐C via carbohydrate response element‐binding protein in glomerular mesangial cells
por: Kitsunai, Hiroya, et al.
Publicado: (2016)

Implication of intracellular localization of transcriptional repressor PLZF in thyroid neoplasms
por: Matsuzawa, Kazuhiko, et al.
Publicado: (2014)

Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8
por: Takiyama, Yumi, et al.
Publicado: (2018)

Hypoxia and Hypoxia-Inducible Factors in Kidney Injury and Repair
por: Shu, Shaoqun, et al.
Publicado: (2019)

Hypoxia and chronic kidney disease
por: Wang, Bin, et al.
Publicado: (2022)

Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014
por: Kume, Shinji, et al.
Publicado: (2019)

Hypoxia-Inducible Factors and Diabetic Kidney Disease—How Deep Can We Go?
por: Stanigut, Alina Mihaela, et al.
Publicado: (2022)

Abnormal Angiogenesis in Diabetic Nephropathy
por: Nakagawa, Takahiko, et al.
Publicado: (2009)

Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease
por: Hirakawa, Yosuke, et al.
Publicado: (2017)

Hypoxia and hypoxia-inducible factors in diabetes and its complications
por: Catrina, Sergiu-Bogdan, et al.
Publicado: (2021)

New glycemic targets for patients with diabetes from the Japan Diabetes Society
por: Araki, Eiichi, et al.
Publicado: (2016)

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen
por: Nitta, Kyoko, et al.
Publicado: (2016)

Insulin in podocyte podiatry
por: Makino, Yuichi, et al.
Publicado: (2011)

Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2020)

Randomized trial of an intensified, multifactorial intervention in patients with advanced‐stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan)
por: Shikata, Kenichi, et al.
Publicado: (2020)

Phosphodiesterase Inhibitor Improves Renal Tubulointerstitial Hypoxia of the Diabetic Rat Kidney
por: Sun, Hui-Kyoung, et al.
Publicado: (2012)

Renal histological heterogeneity and functional progress in normoalbuminuric and microalbuminuric Japanese patients with type 2 diabetes
por: Moriya, Tatsumi, et al.
Publicado: (2014)

Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease
por: Liu, Jing, et al.
Publicado: (2017)

Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes
por: Kawakami, Takahisa, et al.
Publicado: (2014)

Combined changes in albuminuria and kidney function and subsequent risk for kidney failure in type 2 diabetes
por: Oshima, Megumi, et al.
Publicado: (2021)

Mitochondrial Reactive Oxygen Species and Kidney Hypoxia in the Development of Diabetic Nephropathy
por: Schiffer, Tomas A., et al.
Publicado: (2017)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
por: Yanagimachi, Tsuyoshi, et al.
Publicado: (2020)

Editorial: Hypoxia in Kidney Disease
por: Palm, Fredrik, et al.
Publicado: (2018)

Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2019)

Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus
por: Nakamura, Jiro, et al.
Publicado: (2017)

Japanese Clinical Practice Guideline for Diabetes 2016
por: Haneda, Masakazu, et al.
Publicado: (2018)

Nocturnal Hypoxia and Loss of Kidney Function
por: Ahmed, Sofia B., et al.
Publicado: (2011)

A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
por: Hayashi, Hidemi, et al.
Publicado: (2022)

Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease
por: Kaplan, Joshua M., et al.
Publicado: (2018)

Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients
por: Kadowaki, Takashi, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
por: Samukawa, Yoshishige, et al.
Publicado: (2018)

Effects of hypoxia on bone metabolism and anemia in patients with chronic kidney disease
por: Kan, Chao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lkio407mdft3puivnk5gd4as6a